Holen Sie sich die Stockscreener-App
77.44
6.02%
4.40
Handel nachbörslich:
77.50
0.06
+0.08%
Schlusskurs vom Vortag:
$73.04
Offen:
$74.88
24-Stunden-Volumen:
66,908
Relative Volume:
1.33
Marktkapitalisierung:
$477.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-33.67
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
+16.89%
1M Leistung:
+154.57%
6M Leistung:
+106.07%
1J Leistung:
+1,398%
1-Tages-Spanne:
$68.16
$79.80
1-Wochen-Bereich:
$60.43
$79.80
52-Wochen-Spanne:
$4.50
$79.80
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
77.44 | 450.65M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-09 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-08-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Monopar Therapeutics stock price target raised to $95 by Piper Sandler - Investing.com India
Monopar Therapeutics Announces Underwriting Agreement for Stock Sale - msn.com
Piper Sandler Raises Monopar Therapeutics (MNPR) Price Target to - GuruFocus
MNPR: BTIG Raises Price Target on Monopar Therapeutics to $104 | - GuruFocus
Monopar Therapeutics (MNPR): Chardan Capital Raises Price Target - GuruFocus
Chardan Raises Price Target on Monopar Therapeutics to $85 From $60, Keeps Buy Rating - MarketScreener
Goldman Sachs Group Inc. Takes $673,000 Position in Monopar Therapeutics Inc. $MNPR - Defense World
Monopar Therapeutics stock price target raised to $104 by BTIG - Investing.com Canada
Positive Outlook for Monopar Therapeutics’ ALXN1840 Amid New Copper Balance Findings - TipRanks
Lake Street Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $106 - 富途牛牛
Monopar Therapeutics (MNPR) Sees Share Increase Amid Positive St - GuruFocus
Monopar jumps after doctor letter in Journal of Hepatology - TipRanks
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsEarnings Performance Report & Risk Managed Investment Entry Signals - newser.com
Monopar Therapeutics Prices $135 Million Offering of Common Stock, Pre-Funded Warrants - MarketScreener
Monopar Therapeutics (MNPR) Launches $100M Stock Offering - GuruFocus
Monopar Therapeutics prices $100 million stock offering - Investing.com
Monopar Announces Pricing Of $19.2 Mln Public Offering Of Common Stock - Nasdaq
$135 Million Raise: Biotech Monopar Therapeutics Prices Major Stock Offering with $35M Buyback Plan - Stock Titan
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients - The Manila Times
Monopar Therapeutics announces pricing of $135 million underwritten offering of common stock and pre-funded warrants - MarketScreener
Breakthrough: -0.367mg Daily Copper ReductionMonopar's Drug Shows Promise for Wilson Disease Patients - Stock Titan
Monopar Therapeutics Inc. Reports Peer-Reviewed Publication Highlighting ALXN1840's Efficacy in Improving Copper Balance for Wilson Disease Patients - Quiver Quantitative
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Inc.
Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - Nasdaq
Lake Street Initiates Monopar Therapeutics at Buy With $106 Price Target - MarketScreener
Full technical analysis of Monopar Therapeutics Inc. stockEarnings Miss & Community Supported Trade Ideas - newser.com
Monopar Therapeutics (MNPR) Hosts Virtual Meeting with Piper San - GuruFocus
Risk adjusted return profile for Monopar Therapeutics Inc. analyzed2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
Using portfolio simulators with Monopar Therapeutics Inc. includedGap Down & Stepwise Trade Signal Implementation - newser.com
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to S&P Global BMI Index - MarketScreener
Monopar Therapeutics Hits New 52-Week High of $54.54 - Markets Mojo
Monopar Therapeutics (NASDAQ:MNPR) Given "Buy" Rating at Chardan Capital - MarketBeat
Aug Fed Impact: Can DXLG keep up with sector leadersTrade Exit Summary & Real-Time Volume Triggers - khodrobank.com
Can volume confirm reversal in Monopar Therapeutics Inc.Earnings Summary Report & Detailed Earnings Play Alerts - newser.com
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsEarnings Growth Summary & Low Drawdown Investment Ideas - newser.com
Forecast Cut: How liquid is MMSI stock2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - khodrobank.com
Analyzing recovery setups for Monopar Therapeutics Inc. investorsDay Trade & Community Consensus Trade Alerts - newser.com
Breakouts Watch: Does Skeena Resources Limited have declining or rising EPS2025 Volatility Report & Capital Efficiency Focused Ideas - khodrobank.com
Macro Review: Does Monopar Therapeutics Inc stock have upside surprise potentialOil Prices & Weekly Return Optimization Alerts - خودرو بانک
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.July 2025 Summary & High Yield Equity Trading Tips - newser.com
What MACD and RSI say about Monopar Therapeutics Inc.Portfolio Gains Report & Accurate Buy Signal Notifications - newser.com
Monopar Therapeutics Stock Soars to New 52-Week High of $58.94 - Markets Mojo
Monopar Therapeutics Hits New 52-Week High at $68.18 - Markets Mojo
Understanding Monopar Therapeutics Inc.’s price movementSell Signal & Weekly Return Optimization Plans - newser.com
Stop Loss: Will Monopar Therapeutics Inc benefit from sector rotationFed Meeting & Reliable Volume Spike Alerts - خودرو بانک
Quarterly Recap: What is Pearson plc Depositary Receipts 5 year growth outlookEarnings Miss & Low Risk Growth Stock Ideas - خودرو بانک
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Is Monopar Therapeutics Inc. stock ready for a breakoutGDP Growth & Safe Entry Trade Reports - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from BTIG Research - Defense World
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):